Bifidobacterium breve

What it is

Bifidobacterium breve is a prominent anaerobic probiotic bacterium indigenous to the human gastrointestinal tract and human milk. Utilised extensively in clinical probiotic formulations, B. breve is produced through high-density bacterial fermentation followed by freeze-drying. Within Velobiotics products, the strain is encapsulated using patented lipid MEP technology, ensuring high survival rates through stomach acid so that viable bacteria reach the distal gut to exert physiological benefits.

Also known as: B. breve

What it does

• Fosters a balanced gut microbiome and smooth digestion.
• Helps metabolise plant oligosaccharides into beneficial fatty acids.
• Supports skin moisture balance via gut-skin axis pathways.
• Promotes healthy metabolic and immune responses.

Amplified by probiotics

Bifidobacterium breve plays a key role in multi-strain gut microbial networks by fermenting indigestible plant sugars and prebiotics into acetate and lactate. These metabolic byproducts lower intestinal pH, creating optimal conditions for lactic acid bacteria and discouraging acid-sensitive pathogens. Through metabolic cross-feeding, neighboring butyrate-producing bacteria convert B. breve-derived acetate into butyrate, strengthening gut tight junction proteins and reducing systemic endotoxin translocation. Co-administration with strains like Lactobacillus rhamnosus enhances mucosal colonization and immune signaling. Protected by Velobiotics MEP microencapsulation against gastric acid, B. breve reliably colonises the colon, optimizing nutrient absorption and modulating metabolic markers.

Typical dose

1–10 billion CFU/day

The evidence

Clinical trials show that Bifidobacterium breve supplementation supports abdominal comfort, bowel regularity, and gut barrier function across diverse age groups. Meta-analyses also highlight its positive influence on metabolic parameters and skin moisture via gut-skin immune signaling. (Yang K 2026, J Microbiol Biotechnol) (Montarsolo P 2026, Minerva Gastroenterol (Torino)) (Tsuji H 2026, Pediatr Neonatol)

1. Yang K, et al. The Effect of a Probiotic on Gut Microbiota Stability and Systemic Well-Being during Short-Term Travel. J Microbiol Biotechnol. 2026;36:e2510037 PubMed ↗
2. Montarsolo P, et al. Efficacy of a probiotic-prebiotic mix on chronic constipation symptoms in the elderly: results of a pilot study. Minerva Gastroenterol (Torino). 2026;72:123-130 PubMed ↗
3. Tsuji H, et al. Early establishment of Bifidobacterium-dominant microbiome in planned cesarean-born infants via Bifidobacterium breve strain Yakult supplementation: A randomized, double-blind, placebo-controlled, parallel-group pilot study. Pediatr Neonatol. 2026;67:532-540 PubMed ↗

Safety & who should check first

Bifidobacterium breve is generally recognized as safe and well tolerated in clinical studies. No severe adverse effects have been reported in healthy populations, though immunocompromised individuals should consult a healthcare provider.